18F-阿尔法肽II PET/CT用于乳腺癌识别:一项初步临床研究
研究纳入44例疑似原发性乳腺癌女性患者,在7天内分别行18F-阿尔法肽II与18F-FDG PET/CT,经组织病理学确认42个乳腺癌病灶和11个良性乳腺病灶。18F-阿尔法肽II对乳腺癌的识别性能良好但不优于18F-FDG;两者联合可提高敏感度和阴性预测值。
要点
- 18F-阿尔法肽II与18F-FDG对乳腺癌病灶的摄取均高于良性病灶(P<0.05)。
- 两者联合后敏感度升至97.6%、阴性预测值升至85.7%,特异度保持54.5%。
- 18F-阿尔法肽II在雌激素受体强阳性且HER-2表达阴性的乳腺癌中可能优于18F-FDG。
核心结论
- 18F-阿尔法肽II适合用于乳腺癌患者的临床使用。
- 18F-阿尔法肽II识别乳腺癌性能良好,但不优于18F-FDG。
- 18F-阿尔法肽II在检测雌激素受体强阳性且HER-2表达阴性的乳腺癌方面可能优于18F-FDG。
研究设计与样本
- 招募44例疑似原发性乳腺癌女性患者,在7天内采集18F-阿尔法肽II与18F-FDG PET/CT图像。
- 通过视觉分析及SUVmax和SUVmean半定量分析评估乳腺病灶的示踪剂摄取。
- 44例患者经组织病理学确认42个乳腺癌病灶和11个良性乳腺病灶。
主要发现
- 18F-阿尔法肽II和18F-FDG在乳腺癌病灶中的摄取均高于良性乳腺病灶(18F-阿尔法肽II P<0.05,18F-FDG P<0.05)。
- 18F-阿尔法肽II的曲线下面积略小于18F-FDG。
- 鉴别乳腺癌与良性乳腺病灶:18F-阿尔法肽II vs 18F-FDG敏感度88.1% vs 90.5%,阳性预测值88.1% vs 88.4%,特异度54.5% vs 54.5%,阴性预测值54.5% vs 60.0%。
- 联合18F-阿尔法肽II与18F-FDG后敏感度显著升至97.6%、阴性预测值显著升至85.7%,阳性预测值略升至89.1%,特异度不变为54.5%。
- 乳腺癌病灶中18F-阿尔法肽II摄取(SUVmax 3.77±1.78)显著低于18F-FDG摄取(SUVmax 7.37±4.48)(P<0.05)。
关键数值与推荐
- 18F-阿尔法肽II在三阴性亚型中的摄取显著低于luminal A和luminal B亚型。
- HER-2过表达亚型的18F-FDG摄取高于其他3个亚型。
- 8个乳腺癌病灶的18F-阿尔法肽II摄取高于18F-FDG摄取,这些病灶均具有HER-2表达阴性且雌激素受体表达强阳性的共同特征。
临床怎么用
- 18F-阿尔法肽II适合用于乳腺癌患者的临床使用。
- 18F-阿尔法肽II识别乳腺癌性能良好,但不优于18F-FDG。
- 18F-阿尔法肽II在检测雌激素受体强阳性且HER-2表达阴性的乳腺癌方面可能优于18F-FDG。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
18F-alfatide II has been proven to have excellent clinical translational potential. In this study, we investigated 18F-alfatide II for identifying breast cancer and compared the performances between 18F-alfatide II and 18F-FDG. Methods: Forty-four female patients with suspected primary breast cancer were recruited. PET/CT images using 18F-alfatide II and 18F-FDG were acquired within 7 d. Tracer uptake in breast lesions was evaluated by visual analysis, and semiquantitative analysis with SUVmax and SUVmeanResults: Forty-two breast cancer lesions and 11 benign breast lesions were confirmed by histopathology in 44 patients. Both 18F-alfatide II and 18F-FDG had higher uptake in breast cancer lesions than in benign breast lesions (P < 0.05 for 18F-alfatide II, P < 0.05 for 18F-FDG). The area under the curve of 18F-alfatide II was slightly less than that of 18F-FDG. Both 18F-alfatide II and 18F-FDG had high sensitivity (88.1% vs. 90.5%), high positive predictive value (88.1% vs. 88.4%), moderate specificity (54.5% vs. 54.5%), and moderate negative predictive value (54.5% vs. 60.0%) for differentiating breast cancer from benign breast lesions. By combining 18F-alfatide II and 18F-FDG, the sensitivity and negative predictive value significantly increased to 97.6% and 85.7%, respectively, with positive predictive value slightly increased to 89.1% and no change to the specificity (54.5%). The uptake of 18F-alfatide II (SUVmax: 3.77 ± 1.78) was significantly lower than that of 18F-FDG (SUVmax: 7.37 ± 4.48) in breast cancer lesions (P < 0.05). 18F-alfatide II uptake in triple-negative subtype was significantly lower than that in luminal A and luminal B subtypes. By contrast, human epidermal growth factor receptor-2 (HER-2)-overexpressing subtype had higher 18F-FDG uptake than the other 3 subtypes. There were 8 breast cancer lesions with higher 18F-alfatide II uptake than 18F-FDG uptake, which all had a common characteristic that HER-2 expression was negative and estrogen receptor expression was strongly positive. Conclusion:18F-alfatide II is suitable for clinical use in breast cancer patients. 18F-alfatide II is of good performance, but not superior to 18F-FDG in identifying breast cancer. 18F-alfatide II may have superiority to 18F-FDG in detecting breast cancer with strongly positive estrogen receptor expression and negative HER-2 expression.
引用
- Wu J, Wang S, Zhang X, et al. 18F-Alfatide II PET/CT for Identification of Breast Cancer: A Preliminary Clinical Study. J Nucl Med. 2018. PMID: 29700127. doi:10.2967/jnumed.118.208637
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。